The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.

October 4, 2024 | Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.